Möchten Sie immer auf dem neuesten Stand bleiben?

GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time...

WHITE PLAINS, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Iantrek, Inc., a pioneer and leader in bio-interventional ophthalmic surgery (BIOS), today announced the introduction and US controlled release...

PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22%...

Dublin, March 23, 2026 (GLOBE NEWSWIRE) -- The "U.S. AI-driven Diabetic Retinopathy Screening Market Size, Share & Trends Analysis Report by Component, Screening, Deployment Mode, End Use, and...

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

Artelo Biosciences (NASDAQ: ARTL) enters ophthalmology space with a fully funded evaluating ART27.13 in glaucoma patients.

ZUG, Switzerland, March 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected...

Optivate Is Here: A New Name, a Bolder Vision, and Continued Commitment to Elevating Ophthalmology